GC Wealth Management RIA LLC Has $298.96 Million Position in Tempus AI, Inc. $TEM

GC Wealth Management RIA LLC lowered its holdings in Tempus AI, Inc. (NASDAQ:TEM) by 2.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,611,211 shares of the company’s stock after selling 150,296 shares during the quarter. Tempus AI accounts for about 12.4% of GC Wealth Management RIA LLC’s investment portfolio, making the stock its biggest holding. GC Wealth Management RIA LLC’s holdings in Tempus AI were worth $298,959,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Voloridge Investment Management LLC lifted its stake in Tempus AI by 183.0% during the 3rd quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company’s stock valued at $129,708,000 after acquiring an additional 1,039,176 shares during the period. AQR Capital Management LLC purchased a new position in shares of Tempus AI during the second quarter valued at approximately $54,020,000. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Tempus AI by 23.4% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock valued at $195,636,000 after purchasing an additional 821,490 shares during the last quarter. Amova Asset Management Americas Inc. lifted its position in Tempus AI by 23.4% during the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after purchasing an additional 821,490 shares during the period. Finally, Vanguard Group Inc. lifted its position in Tempus AI by 8.7% during the fourth quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock valued at $605,772,000 after purchasing an additional 817,014 shares during the period. 24.22% of the stock is owned by institutional investors.

Insider Activity at Tempus AI

In other news, CFO James William Rogers sold 11,529 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $55.00, for a total value of $634,095.00. Following the completion of the sale, the chief financial officer owned 114,866 shares in the company, valued at approximately $6,317,630. This trade represents a 9.12% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Ryan M. Bartolucci sold 4,116 shares of the firm’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total transaction of $181,392.12. Following the completion of the sale, the chief accounting officer directly owned 74,041 shares of the company’s stock, valued at approximately $3,262,986.87. The trade was a 5.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 616,043 shares of company stock worth $31,748,593 in the last ninety days. Corporate insiders own 24.26% of the company’s stock.

Wall Street Analysts Forecast Growth

TEM has been the subject of a number of research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tempus AI in a research report on Wednesday, June 17th. Jefferies Financial Group initiated coverage on Tempus AI in a research report on Monday, April 13th. They issued an “underperform” rating and a $35.00 target price on the stock. TD Cowen restated a “buy” rating on shares of Tempus AI in a research note on Wednesday, July 15th. Wall Street Zen lowered shares of Tempus AI from a “hold” rating to a “sell” rating in a research report on Saturday, July 4th. Finally, BTIG Research reiterated a “buy” rating and issued a $80.00 price objective on shares of Tempus AI in a research note on Monday, June 1st. Nine equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $68.92.

Tempus AI Trading Down 2.0%

TEM stock opened at $46.01 on Friday. The company has a debt-to-equity ratio of 2.96, a current ratio of 3.31 and a quick ratio of 3.15. Tempus AI, Inc. has a 1-year low of $41.73 and a 1-year high of $104.32. The business has a 50 day simple moving average of $51.67 and a two-hundred day simple moving average of $53.64. The company has a market capitalization of $8.26 billion, a price-to-earnings ratio of -26.75 and a beta of 3.46.

Tempus AI (NASDAQ:TEM) last issued its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.08. The firm had revenue of $348.12 million for the quarter, compared to analysts’ expectations of $345.44 million. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The business’s revenue was up 36.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.24) earnings per share. Research analysts anticipate that Tempus AI, Inc. will post -1.33 EPS for the current fiscal year.

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.